Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02172651 · ClinicalTrials.gov registry record · Early Phase 1
Vitamin D in Patients With Stage I-III Colon Cancer or Resectable Colon Cancer Liver Metastases
A Early Phase 1 study of Stage, Colon Cancer and Stage I-III Colon Cancer, sponsored by Dana-Farber Cancer Institute.
- Recruiting
- Registry status
- Early Phase 1
- Development phase
- 80
- Enrollment target
- 1
- Study location
NCT02172651 is a Early Phase 1 study of Stage, Colon Cancer and Stage I-III Colon Cancer that is actively recruiting participants, run by Dana-Farber Cancer Institute. The registered enrollment target is 80 participants. The trial reports 1 study location across 1 state.
The verdict
NCT02172651, a Early Phase 1 study of Stage, Colon Cancer and Stage I-III Colon Cancer, is actively recruiting participants, sponsored by Dana-Farber Cancer Institute.
- RECRUITING
- Registry status
- Early Phase 1
- Development phase
- 80 participants
- Enrollment target
- 1
- Study location
Study Summary
This study seeks to learn more about the vitamin D receptor and its relationship to colon cancer. The Vitamin D receptor is found in colon cancer cells. When Vitamin D binds to the receptor in the cancer cells, it may stop cancer cells from growing abnormally and may cause cancer cell death. Vitamin D has been used in other research studies and information from those other research studies suggests that Vitamin D may help in the treatment of colon cancer. Participants will receive either high-dose vitamin D or standard-dose vitamin D. The study drug will be given 14-28 days prior to your surgery. The number of days will depend on when the surgery is scheduled.
Conditions Studied
Interventions
- DRUG Placebo
- DRUG Vitamin D3
Study Locations (1)
Massachusetts
- Dana-Farber Cancer Institute - Boston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 80 participants |
| Start Date | 2014-07-14 |
| Est. Completion | 2026-06-30 |
| Phase | Early Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02172651
The ClinicalTrials.gov registry entry for NCT02172651 describes a study currently listed as recruiting, categorized as Early Phase 1. The registered enrollment target is 80 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Dana-Farber Cancer Institute, which has 781 total studies on file at ClinicalTrials.gov.
The record links to 3 conditions, with Stage, Colon Cancer appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT02172651 reports 1 study location spanning 1 distinct geographic area - top geographies include Massachusetts.
Frequently Asked Questions
What is clinical trial NCT02172651 about?
NCT02172651 is a clinical study titled "Vitamin D in Patients With Stage I-III Colon Cancer or Resectable Colon Cancer Liver Metastases". This study seeks to learn more about the vitamin D receptor and its relationship to colon cancer. The Vitamin D receptor is found in colon cancer cells. When Vitamin D binds to the receptor in the cancer cells, it may stop cancer cells from growing abnormally and may cause cancer cell death. Vitamin...
What is the current status of trial NCT02172651?
This trial is currently recruiting. It is a Early Phase 1 study. The enrollment target is 80 participants. The study started on 2014-07-14. Estimated completion is 2026-06-30.
What conditions does trial NCT02172651 study?
This clinical trial studies the following conditions: Stage, Colon Cancer, Stage I-III Colon Cancer, Stage IV Colon Cancer With Resectable Liver Metastases.
What interventions are being tested in trial NCT02172651?
The interventions under investigation include: Placebo (DRUG), Vitamin D3 (DRUG).
Who is sponsoring clinical trial NCT02172651?
This trial is sponsored by Dana-Farber Cancer Institute, which has 781 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02172651 being conducted?
This trial has 1 study location across Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.